Midazolam is a short-acting drug of the benzodiazepine class, which is used to treat acute seizures, moderately severe insomnia , to stimulate sedation and amnesia before medical procedures, and also as a fatal injection [1] . It has powerful anxiolytic, amnestic , hypnotic , anticonvulsant , sedative effects, and also relaxes skeletal muscles . [2] [3] [4] Midazolam has a fast recovery time and is the most commonly used benzodiazepine for sedation; less often it is used to induce and maintain anesthesia . Flumazenil is an antagonist of benzodiazepines, which can be used to treat an overdose of midazolam, as well as to cancel the effect of sedation. [3] However, flumazenil can provoke seizures in mixed overdoses and in individuals with benzodiazepine dependence, so it is not used in most cases. [5] [6]
| Midazolam | |
|---|---|
| Midazolam | |
| Chemical compound | |
| IUPAC | 8-Chloro-6- (2-fluorophenyl) -1-methyl-4 H- imidazo [1,5-a] [1,4] benzodiazepine (as hydrochloride or maleate) |
| Gross formula | C 18 H 13 ClFN 3 |
| Molar mass | 325.78 |
| Cas | |
| PubChem | |
| Drugbank | |
| Classification | |
| ATX | |
| Pharmacokinetics | |
| Bioavailable | Inside ~ 36% V / m 90% + |
| Metabolism | The liver |
| The half-life. | 1.8-6.4 hours |
| Excretion | The kidneys |
| Other names | |
| Flormidal, Dormicum, Fulsed | |
The use of midazolam intranasally (through the nose) or intrabuccally (absorption through the gums and cheeks), as an alternative to the rectal administration of diazepam , is becoming increasingly popular for emergency treatment of seizures in children. [7] Midazolam is also used for sedation in endoscopic procedures [8] and in intensive care. [9] [10] The ability of midazolam to cause anterograde amnesia is useful for premedication before surgery, as it eliminates unpleasant memories. [11] Midazolam, like many other benzodiazepines, has a rapid onset of action, high efficacy, and low toxicity. The disadvantages of midazolam include drug interactions, the development of tolerance, withdrawal syndrome, as well as side effects, including cognitive impairment and relaxation. [11] Paradoxical effects occur most often in children, the elderly [11] and especially after intravenous administration. [12]
History
Midazolam is one of the 35 benzodiazepines that are currently used in medical practice. [13] It was synthesized in 1976 by Walser and Fryer at Hoffmann – La Roche in the United States. [14] It was found that due to its solubility in water, midazolam causes thrombophlebitis less frequently than similar drugs. [15] [16] In the same year, the benzodiazepine drug alprazolam was synthesized from midazolam [17] [18] and was introduced to the US pharmacological market in 1981. [19] The anticonvulsant properties of midazolam were studied in the late 1970s, but it was not used until the 1990s until its effectiveness in treating convulsive status epilepticus was revealed. [20] As of 2010, it is the most commonly used benzodiazepine in anesthesiology. [21] In critical state medicine, midazolam is becoming more popular than other benzodiazepines, such as lorazepam and diazepam, because it is of shorter action, is more powerful and causes less pain at the injection site. [13] Midazolam is also becoming increasingly popular in veterinary medicine due to its solubility in water. [22]
Indications
Midazolam is indicated intravenously for sedation (often in combination with an opioid , such as fentanyl ), as well as for premedication in the preoperative period, for the induction of anesthesia and for sedation of patients with mechanical ventilation in the intensive care unit. [9] [10] Midazolam is superior to diazepam in memory depression in endoscopic procedures, but propofol has a faster recovery time and has a better memory inhibition effect. [8] This is the most popular benzodiazepine in the intensive care unit (ICU) because of its short half-life combined with its solubility in water and its suitability for continuous infusion. However, for long-term sedation, lorazepam is preferable because of its long duration of action [23] and propofol has advantages over midazolam when used in ICU for sedation in cases of short excommunication and early tracheal extubation. [24] It has been proven that intrabuccal (absorption through the cheeks) and intranasal (through the nose) administration of midazolam is easier and more effective than rectal administration of diazepam in controlling seizures. [25] [26] [27] Patients with incurable pathologies may be given midazolam subcutaneously in low doses in the last hours or days of life to reduce arousal, myoclonus , anxiety or anxiety. [28] The use of higher doses of midazolam during the last weeks of life is considered preferred in palliative therapy for continuous and deep sedation, when it is necessary to alleviate the patient's unbearable suffering with the ineffectiveness of other methods of treatment; [29] but the need for this is rarer. [30] Midazolam is also sometimes used in newborns who have mechanical ventilation, but morphine is preferable in this situation, since it is safer. [31]
Midazolam is indicated orally for the short-term treatment of moderately severe insomnia in patients in whom other sleeping pills have been found to be ineffective and who constantly have trouble falling asleep. Since midazolam has an extremely short duration of action, it is not prescribed for patients who have problems staying in sleep all night; in such situations, medium and long-acting benzodiazepines are used ( temazepam , nitrazepam , flunitrazepam ).
General Information
Available in the form of maleate and hydrochloride. In structure and action, it is close to benzodiazepine tranquilizers . It has a calming, anticonvulsant, muscle relaxant effect, enhances the effect of sleeping pills, drugs, analgesics.
A characteristic feature of midazolam is a pronounced hypnotic (hypnotic) effect, in connection with which the drug is used mainly in anesthetic practice for sedation, anesthesia and maintenance of anesthesia.
Midazolam is administered intravenously and intramuscularly. The drug does not last long. For premedication, midazolam is administered 20-30 minutes before anesthesia intramuscularly at 0.05-0.1 mg / kg. It can be used alone or in combination with anticholinergics and analgesics.
For anesthesia, they are administered intravenously for 15 minutes at the rate of 0.15-0.25 mg / kg, together with analgesics. To maintain anesthesia, additional doses are administered. Midazolam and ketamine can be combined.
With the intravenous administration of midazolam, respiratory depression may develop, therefore its use is allowed only if ventilation is possible.
Midazolam should not be used for severe myasthenia gravis, circulatory failure, in the first 3 months. pregnancy.
15 mg midazolam tablets are also available, used as a tranquilizing and sleeping pill and for sedation.
Contraindications and special instructions
Benzodiazepines require caution when used in the elderly, pregnant women, children, people with alcohol or drug addiction, as well as patients with concomitant mental disorders . [32] Extra caution is required in critically ill patients, as midazolam and its active metabolites may accumulate. [33] Impaired renal or hepatic function may slow the elimination of midazolam, leading to its longer duration. [3] [34] Contraindications include hypersensitivity, acute angle-closure glaucoma , shock, hypotension , and head injuries. Most of them are relative contraindications.
Pregnancy
The use of midazolam during the third trimester of pregnancy can lead to a serious risk for the newborn , including benzodiazepine withdrawal syndrome with possible symptoms, including hypotension, apnea , cyanosis and metabolic reactions to cold stress. Symptoms of hypotension and benzodiazepine withdrawal symptoms in newborns have been reported to persist from several hours to several months after birth. [35] Other manifestations of withdrawal in newborns include increased irritability, tremors, and gastrointestinal upsets ( diarrhea or vomiting ). Breastfeeding a mother receiving midazolam is not recommended. [36]
Newborns
Midazolam is sometimes used in neonatal intensive care units. When used in newborns, extra care is required; midazolam should not be used for more than 72 hours because of the risk of tachyphylaxis , the possibility of developing a withdrawal syndrome of benzodiazepines, as well as neurological complications. Intravenous jet injections should be avoided due to the increased risk of cardiovascular depression, as well as neurological complications. [37]
Elder
Extra care is also required when using midazolam in the elderly, since they are more sensitive to the pharmacological effects of benzodiazepines, and the metabolism of benzodiazepines is slower. Elderly people are more prone to side effects, including drowsiness , amnesia , especially anterograde, ataxia , a hangover effect, confusion and falling. [eleven]
Side Effects
Side effects of midazolam include tolerance, withdrawal symptoms, confusion, amnesia, especially anterograde, ataxia, drowsiness, cognitive impairment, sedation, and an increased risk of falls in old age. [11] People who experience amnesia as a side effect of midazolam are generally unaware that their memory is getting worse. [38]
Long-term use of benzodiazepines is associated with a prolonged memory deficit and its partial recovery occurs only 6 months after cessation of intake. [11] It remains unclear whether complete recovery occurs after a long period of abstinence from taking. Benzodiazepines can cause or worsen depression. [11] Sometimes, when taking benzodiazepines, paradoxical agitation occurs, including worsening seizures. Children, the elderly, individuals with alcohol abuse or aggressive behavior, a history of anger are at an increased risk of paradoxical effects. [11] Paradoxical reactions especially occur with intravenous administration. [12] After an overnight intake of midazolam, the residual “hangover” effect (ie drowsiness, impaired psychomotor and cognitive functions) may persist the next day. This can impair the ability of the midazolam user to drive safely and may increase the risk of hip falls and fractures . [39] Sedation, respiratory depression, hypotension (as a result of a decrease in total vascular resistance), and an increase in heart rate may occur. [3] [40] Hypotension may occur with rapid administration of midazolam.
In susceptible individuals, midazolam, as you know, can cause paradoxical reactions. At the same time, a person may be anxious, he may experience involuntary movements, aggressive behavior, uncontrolled crying and other similar effects. It is believed that this is due to an altered state of consciousness or disinhibition caused by the drug. The patient often does not remember the paradoxical behavior because of the amnesia caused by the drug. In extreme situations, flumazenil can be used to inhibit or reverse the effect of midazolam. Antipsychotic drugs, such as haloperidol , can also be used for this purpose. [41]
Midazolam is known to cause respiratory depression. In healthy people, 0.15 mg / kg of midazolam can cause respiratory depression. [42] When midazolam is administered in combination with fentanyl, the occurrence of hypoxemia or apnea becomes more likely. [43]
Tolerance, dependence and withdrawal syndrome
Benzodiazepine addiction occurs in about one third of people who are treated with benzodiazepines for more than 4 weeks. [11] Dependence usually leads to tolerance and withdrawal syndrome of benzodiazepines (with a rapid reduction in dose). Midazolam infusions can cause tolerance and withdrawal symptoms within a few days. Risk factors for addiction include personality addiction, the use of short-acting and highly active benzodiazepines, as well as long-term therapy with benzodiazepines. The symptoms of midazolam withdrawal can range from insomnia and anxiety to cramps and psychosis . The withdrawal symptoms can sometimes be similar to the symptoms of the underlying disease in the patient. A gradual decrease in the dose of midazolam after regular use can minimize the symptoms of withdrawal. The emergence of tolerance and withdrawal syndrome may be associated with impaired regulation of receptors and changes in the expression of GABA A receptor genes, which leads to long-term changes in the function of GABAergic system neurons. [11] [44] [45]
In patients receiving midazolam for a long time, the therapeutic effect of the drug is reduced due to the development of tolerance to benzodiazepine. [46] [47] Prolonged infusion of midazolam leads to the development of tolerance; if midazolam is given intravenously for several days or more, withdrawal syndrome may occur. Therefore, in order to prevent the withdrawal syndrome, the termination of a long infusion should be gradual, and sometimes, if necessary, a continued dose reduction with the oral administration of long-acting benzodiazepine, for example, clorazepate dipotassium . When signs of midazolam tolerance occur during intensive care, the use of opioids or propofol for additional sedation is recommended. Withdrawal symptoms may include irritability , the occurrence of pathological reflexes , tremors , muscle twitching, hypertonicity, delirium , seizures , nausea , vomiting and diarrhea , tachycardia , hypertension and tachypnea . [48]
Non-medical use
In several US states , it has been used several times as a component of the death injection during the execution of the death penalty [49] [50] .
Notes
- ↑ Supreme Court: lethal injection is constitutional
- ↑ Mandrioli R., Mercolini L., Raggi MA Benzodiazepine metabolism: an analytical perspective (English) // Curr. Drug Metab. : journal. - 2008 .-- October ( vol. 9 , no. 8 ). - P. 827-844 . - DOI : 10.2174 / 138920008786049258 . - PMID 18855614 . Archived on March 17, 2009. Archived March 17, 2009 on Wayback Machine
- ↑ 1 2 3 4 Olkkola, KT .; Ahonen, J. Midazolam and other benzodiazepines. (neopr.) // Handb Exp Pharmacol. - 2008. - T. 182 , No. 182 . - S. 335-360 . - DOI : 10.1007 / 978-3-540-74806-9_16 . - PMID 18175099 .
- ↑ Barash, Paul G. Clinical Anesthesia / Paul G. Barash, Bruce F. Cullen, Robert K. Stoelting ... [and others. ] . - 6. - Lippincott Williams Wilkins, April 1, 2009. - P. 588. - ISBN 978-0-7817-8763-5 .
- ↑ A. Boon, Nicholas. Davidson's principles practice of medicine / Nicholas A. Boon, Stanley Davidson, Nicki R. Colledge ... [ and others. ] . - Edinburgh: Elsevier / Churchill Livingstone, 2006. - P. 212–213. - ISBN 978-0-443-10057-4 .
- ↑ A Rastegar, Darius. Addiction medicine: an evidence-based handbook / Darius A Rastegar, Michael I Fingerhood. - Philadelphia, PA: Lippincott Williams Wilkins, 2005 .-- P. 80. - ISBN 978-0-7817-6154-3 .
- ↑ Appleton, R .; Macleod, S .; Martland, T .; Appleton, Richard. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. (English) // Cochrane Database of Systematic Reviews : journal. - 2008 .-- 16 July ( no. 3 ). - P. CD001905 . - DOI : 10.1002 / 14651858.CD001905.pub2 . - PMID 18646081 . (inaccessible link)
- ↑ 1 2 McQuaid, KR .; Laine, L. A systematic review and meta-analysis of randomized, controlled trials of moderate sedation for routine endoscopic procedures. (Eng.) // Gastrointest Endosc : journal. - 2008 .-- May ( vol. 67 , no. 6 ). - P. 910-923 . - DOI : 10.1016 / j.gie.2007.12.046 . - PMID 18440381 .
- ↑ 1 2 Brown, TB .; Lovato, LM .; Parker, D. Procedural sedation in the acute care setting. (Eng.) // Am Fam Physician : journal. - 2005 .-- January ( vol. 71 , no. 1 ). - P. 85-90 . - PMID 15663030 .
- ↑ 1 2 O'Connor, M .; Bucknall, T .; Manias, E. Sedation Management in Australian and New Zealand Intensive Care Units: Doctors 'and Nurses' Practices and Opinions. (Eng.) // Am J Crit Care: journal. - 2009 .-- 21 September ( vol. 19 , no. 3 ). - P. 285-295 . - DOI : 10.4037 / ajcc2009541 . - PMID 19770414 .
- ↑ 1 2 3 4 5 6 7 8 9 10 Riss, J .; Cloyd, J .; Gates, J .; Collins, S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. (Eng.) // Acta Neurol Scand : journal. - 2008 .-- August ( vol. 118 , no. 2 ). - P. 69-86 . - DOI : 10.1111 / j.1600-0404.2008.01004.x . - PMID 18384456 . (inaccessible link)
- ↑ 1 2 Rosenbaum, A .; Kain, ZN .; Larsson, P .; Lönnqvist, PA .; Wolf, AR. The place of premedication in pediatric practice. (Eng.) // Paediatr Anaesth : journal. - 2009 .-- September ( vol. 19 , no. 9 ). - P. 817-828 . - DOI : 10.1111 / j.1460-9592.2009.03.034.x . - PMID 19691689 . (inaccessible link)
- ↑ 1 2 Udaykumar, Padmaja. Short Textbook of Pharmacology for Dental and Allied Health Sciences . - Jaypee Brothers Medical Publishers, May 30, 2008 .-- P. 128. - ISBN 978-81-8448-149-5 .
- ↑ Armin Walser, Rodney I. Fryer, Louis Benjamin. Imidazo [1,5-.alpha.] [1,4] benzodiazepines. US Patent 4,166,185, issued to Hoffmann-LaRoche Aug 28, 1979.
- ↑ Kaplan, Joel H. Cardiac Anesthesia / Joel H. Kaplan, David L. Reich, Carol L. Lake ... [ and others. ] . - 5. - WB Saunders Company, 15 May 2006. - ISBN 978-1-4160-0253-6 .
- ↑ Malamed, Stanley F. Sedation: a guide to patient management . - St. Louis: Mosby, October 16, 2002. - P. 335. - ISBN 978-0-323-01226-3 .
- ↑ Vardanyan, Ruben. Synthesis of essential drugs / Ruben Vardanyan, ۊ Ruben Vardanyan, Victor J. Hruby. - Amsterdam: Elsevier, March 10, 2006. - P. 7. - ISBN 978-0-444-52166-8 .
- ↑ Jackson B .; Hester, Jr. 6-Phenyl-4H-s-triazolo [4,3-a [1,4] benzodiazepines] . United States Patent and Trademark Office (October 19, 1976).
- ↑ Walker, Sydney. A dose of sanity: mind, medicine, and misdiagnosis . - New York: John Wiley & Sons, December 3, 1996. - P. 64–65. - ISBN 978-0-471-19262-6 .
- ↑ S. Wheeler, Derek. Pediatric critical care medicine: basic science and clinical evidence / Derek S. Wheeler, Hector R. Wong, Thomas P. Shanley. - London: Springer, 2007 .-- P. 984. - ISBN 978-1-84628-463-2 .
- ↑ Oparil, Suzanne. Hypertension: a companion to Brenner and Rector's the kidney / Suzanne Oparil, Michael Weber. - 2. - Philadelphia: Elsevier Mosby, April 22, 2005 .-- P. 816. - ISBN 978-0-7216-0258-5 .
- ↑ Riviere, Jim. Veterinary Pharmacology and Therapeutics / Jim Riviere, Mark G. Papich. - Wiley-Blackwell, Mar 30, 2009 .-- P. 358. - ISBN 978-0-8138-2061-3 .
- ↑ Arcangeli, A .; Antonelli, M .; Mignani, V .; Sandroni, C. Sedation in PACU: the role of benzodiazepines. (unspecified) // Curr Drug Targets. - 2005. - November ( t. 6 , No. 7 ). - S. 745-748 . - DOI : 10.2174 / 138945005774574416 . - PMID 16305452 .
- ↑ De Cosmo, G .; Congedo, E .; Clemente, A .; Aceto, P. Sedation in PACU: the role of propofol. (unspecified) // Curr Drug Targets. - 2005. - November ( t. 6 , No. 7 ). - S. 741-744 . - DOI : 10.2174 / 138945005774574425 . - PMID 16305451 .
- ↑ Eriksson, K .; Kälviäinen, R. Pharmacologic management of convulsive status epilepticus in childhood. (Eng.) // Expert Rev Neurother: journal. - 2005 .-- November ( vol. 5 , no. 6 ). - P. 777-783 . - DOI : 10.1586 / 14737175.5.6.777 . - PMID 16274335 .
- ↑ Wolfe, TR .; Macfarlane, TC. Intranasal midazolam therapy for pediatric status epilepticus. (neopr.) // Am J Emerg Med . - 2006. - May ( t. 24 , No. 3 ). - S. 343—346 . - DOI : 10.1016 / j.ajem.2005.11.004 . - PMID 16635708 .
- ↑ Sofou, K .; Kristjánsdóttir, R .; Papachatzakis, NE .; Ahmadzadeh, A .; Uvebrant, P. Management of prolonged seizures and status epilepticus in childhood: a systematic review. (Eng.) // J Child Neurol : journal. - 2009 .-- August ( vol. 24 , no. 8 ). - P. 918-926 . - DOI : 10.1177 / 0883073809332768 . - PMID 19332572 .
- ↑ Liverpool Care Pathway. Care of the Dying Pathway (lcp) (Hospital) (PDF) (link not available) (January 2005). Date of treatment February 8, 2010. Archived August 23, 2011.
- ↑ de Graeff, A .; Dean, M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. (Eng.) // J Palliat Med : journal. - 2007 .-- February ( vol. 10 , no. 1 ). - P. 67-85 . - DOI : 10.1089 / jpm.2006.0139 . - PMID 17298256 .
- ↑ Royal College of Physicians . National care of the dying audit 2009 (September 2009). Date of treatment January 20, 2010. Archived January 20, 2010. "[I] n their last 24 hours ... 31% had low doses of medication to [control distress from agitation or restlessness] ... the remaining 4% required higher doses"
- ↑ Bellù, R .; de Waal, KA .; Zanini, R .; Bellù, Roberto. Opioids for neonates receiving mechanical ventilation. (English) // Cochrane Database of Systematic Reviews : journal. - 2008. - No. 1 . - P. CD004212 . - DOI : 10.1002 / 14651858.CD004212.pub3 . - PMID 18254040 .
- ↑ Authier, N .; Balayssac, D .; Sautereau, M .; Zangarelli, A .; Courty, P .; Somogyi, AA .; Vennat, B .; Llorca, PM .; Eschalier, A. Benzodiazepine dependence: focus on withdrawal syndrome. (Eng.) // Ann Pharm Fr : journal. - 2009 .-- November ( vol. 67 , no. 6 ). - P. 408-413 . - DOI : 10.1016 / j.pharma.2009.07.07.001 . - PMID 19900604 .
- ↑ Cox, CE .; Reed, SD .; Govert, JA .; Rodgers, JE .; Campbell-Bright, S .; Kress, JP .; Carson, SS. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. (Eng.) // Crit Care Med : journal. - 2008 .-- March ( vol. 36 , no. 3 ). - P. 706-714 . - DOI : 10.1097 / CCM.0B013E3181544248 . - PMID 18176312 .
- ↑ Verbeeck, RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. (Eng.) // Eur J Clin Pharmacol : journal. - 2008 .-- December ( vol. 64 , no. 12 ). - P. 1147-1161 . - DOI : 10.1007 / s00228-008-0553-z . - PMID 18762933 .
- ↑ McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation (Eng.) // Reprod Toxicol. : journal. - 1994. - Nov-Dec ( vol. 8 , no. 6 ). - P. 461-475 . - DOI : 10.1016 / 0890-6238 (94) 90029-9 . - PMID 7881198 .
- ↑ Serreau, R .; Collége national des gynécologues et obstétriciens; Société française de médecine périnatale; Société française de néonatalogie; Société française de anesthésie et de réanimation. [Drugs during preeclampsia. Fetal risks and pharmacology] (Eng.) // Ann Fr Anesth Reanim: journal. - 2010 .-- April ( vol. 29 , no. 4 ). - P. e37—46 . - DOI : 10.1016 / j.annfar.2010.02.016 . - PMID 20347563 .
- ↑ Rawicz, M. [Recommendations for analgesia and sedation in neonatal intensive care] // Med Wieku Rozwoj: journal. - 2008 .-- Oct-Dec ( vol. 12 , no. 4 Pt 1 ). - P. 958-967 . - PMID 19471072 .
- ↑ Merritt P., Hirshman E., Hsu J., Berrigan M. Metamemory without the memory: are people aware of midazolam-induced amnesia? (Eng.) // Psychopharmacology : journal. - Springer , 2005. - Vol. 177 , no. 3 . - P. 336—343 . - DOI : 10.1007 / s00213-004-1958-8 . - PMID 15290003 .
- ↑ Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications (Eng.) // CNS Drugs. : journal. - 2004. - Vol. 18 , no. 5 . - P. 297—328 . - DOI : 10.2165 / 00023210-200418050-00003 . - PMID 15089115 .
- ↑ Walker, M. Status epilepticus: an evidence based guide. (English) // BMJ : journal. - 2005 .-- September ( vol. 331 , no. 7518 ). - P. 673-677 . - DOI : 10.1136 / bmj.331.7518.673 . - PMID 16179702 .
- ↑ Carissa E. Mancuso, Maria G. Tanzi, Michael Gabay. Paradoxical Reactions to Benzodiazepines: Midazolam (Spanish) // Pharmacotherapy: diario. - 2004.
- ↑ Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ Midazolam: Pharmacology and Uses (English) // Anesthesiology . - Lippincott Williams & Wilkins , 1985.
- ↑ Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA, Stanley TH Frequent hypoxemia and apnea after sedation with midazolam and fentanyl (English) // Anesthesiology : journal. - Lippincott Williams & Wilkins , 1990.
- ↑ Fukuda K., Shoda T., Mima H., Uga H. Midazolam induces expression of c-Fos and EGR-1 by a non-GABAergic mechanism (Eng.) // Anesth. Analg. : journal. - 2002 .-- August ( vol. 95 , no. 2 ). - P. 373-378 . - DOI : 10.1097 / 00000539-200208000-00024 . - PMID 12145054 .
- ↑ Cho HH, O'Connell JP, Cooney MF, Inchiosa MA Minimizing tolerance and withdrawal to prolonged pediatric sedation: case report and review of the literature (English) // J Intensive Care Med : journal. - 2007. - Vol. 22 , no. 3 . - P. 173-179 . - DOI : 10.1177 / 0885066607299556 . - PMID 17569173 .
- ↑ Potokar J., Coupland N., Wilson S., Rich A., Nutt D. Assessment of GABA (A) benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines (Eng.) // Psychopharmacology : journal. - Springer , 1999 .-- September ( vol. 146 , no. 2 ). - P. 180-184 . - DOI : 10.1007 / s002130051104 . - PMID 10525753 . Archived January 12, 2002. Archived January 12, 2002 on the Wayback Machine
- ↑ Mencía, SB .; López-Herce, JC .; Freddi, N. Analgesia and sedation in children: practical approach for the most frequent situations. (English) // J Pediatr (Rio J): journal. - 2007 .-- May ( vol. 83 , no. 2 Suppl ). - P. S71-82 . - DOI : 10.2223 / JPED.1625 . - PMID 17530139 .
- ↑ Mencía, SB .; López-Herce, JC .; Freddi, N. Analgesia and sedation in children: practical approach for the most frequent situations. (English) // J Pediatr (Rio J): journal. - 2007 .-- May ( vol. 83 , no. 2 Suppl ). - P. S71-82 . - DOI : 10.2223 / JPED.1625 . - PMID 17530139 .
- ↑ rbc. In the United States, those sentenced to death opposed a new lethal injection (Rus.) : Journal. - 2013.
- ↑ In the USA, a new lethal injection was used for execution , the Internet portal of the Rossiyskaya Gazeta (January 17, 2014). Date of treatment August 14, 2016.